In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S.
Rifkin RM, et al. Among authors: noga sj.
Future Oncol. 2024 Jan;20(3):131-143. doi: 10.2217/fon-2023-0272. Epub 2023 Oct 9.
Future Oncol. 2024.
PMID: 37807952
Free article.